PHP
NBIX icon

Parkman Healthcare Partners’s Neurocrine Biosciences NBIX Stock Holding History

Parkman Healthcare Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-99,069
Closed -$13.1M – 94
2026
Q1 		$13.1M Sell
99,069
-15,643
-14% -$2.08M 1.35% 25
2025
Q4 		$16.3M Sell
114,712
-27,110
-19% -$3.93M 1.55% 20
2025
Q3 		$19.9M Sell
141,822
-24,188
-15% -$3.28M 2.08% 15
2025
Q2 		$20.9M Sell
166,010
-2,372
-1% -$272K 2.4% 11
2025
Q1 		$18.6M Buy
168,382
+52,655
+45% +$6.67M 2.21% 13
2024
Q4 		$15.8M Sell
115,727
-14,113
-11% -$1.75M 2.1% 15
2024
Q3 		$15M Buy
129,840
+14,670
+13% +$2.01M 1.91% 17
2024
Q2 		$15.9M Sell
115,170
-16,781
-13% -$2.3M 2.12% 12
2024
Q1 		$18.2M Sell
131,951
-8,165
-6% -$1.12M 2.23% 11
2023
Q4 		$18.5M Buy
140,116
+56,271
+67% +$6.48M 2.6% 10
2023
Q3 		$9.43M Sell
83,845
-55,890
-40% -$5.89M 1.73% 15
2023
Q2 		$13.2M Sell
139,735
-78,103
-36% -$7.63M 2.28% 13
2023
Q1 		$22M Buy
217,838
+101,505
+87% +$10.6M 4.8% 2
2022
Q4 		$13.9M Sell
116,333
-1,067
-0.9% -$125K 3.7% 4
2022
Q3 		$12.5M Buy
117,400
+31,811
+37% +$3.23M 3.55% 5
2022
Q2 		$8.34M Buy
85,589
+22,355
+35% +$2.06M 3.07% 9
2022
Q1 		$5.93M Buy
+63,234
New +$5.36M 1.73% 20
2020
Q4 		– Sell
-132,544
Closed -$12.7M – 93
2020
Q3 		$12.7M Buy
132,544
+11,018
+9% +$1.27M 3.37% 3
2020
Q2 		$14.8M Sell
121,526
-7,000
-5% -$774K 4.18% 1
2020
Q1 		$11.1M Sell
128,526
-26,899
-17% -$2.63M 5.16% 2
2019
Q4 		$16.7M Buy
+155,425
New +$16.3M 4.82% 2

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Parkman Healthcare Partners's NBIX Position: Q2 2026 in Review

Parkman Healthcare Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 99,069 shares — an estimated $13.1M sold.

Parkman Healthcare Partners first reported a position in NBIX in Q4 2019 and held it in 21 quarters. The position peaked at $22M in Q1 2023. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Parkman Healthcare Partners reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Parkman Healthcare Partners sold 99,069 Neurocrine Biosciences shares in Q2 2026, an estimated $13.1M.
  • Parkman Healthcare Partners first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 21 quarters.
  • Parkman Healthcare Partners's Neurocrine Biosciences position peaked at $22M in Q1 2023.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.